Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

RYAN E HALL

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1366761975
CMS profile
1028578
Location
LITTLE ROCK, AR

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$88.44

5 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $88.44 5

By paying entity

PY2025 · entire year · sorted by reported total

Paying entityAmountRecords
Caris MPI, Inc. $29.22 2
GENZYME CORPORATION $20.86 1
Gilead Sciences, Inc. $19.22 1
Azurity Pharmaceuticals, Inc. $19.14 1

Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

RYAN E HALL

NPI 1366761975 · CMS profile ID 1028578

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

LITTLE ROCK, AR

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1366761975?year=2025&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
RYAN E HALL, NPI 1366761975, CMS profile ID 1028578. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1366761975?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). RYAN E HALL, NPI 1366761975, CMS profile ID 1028578. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1366761975?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
RYAN E HALL, NPI 1366761975, CMS profile ID 1028578, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1366761975?year=2025&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

5 matching records · $88.44 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 5 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–5 of 5.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Caris MPI, Inc. $15.4212/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234280917 CMS
Caris MPI, Inc. $13.8012/01/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234280915 CMS
Azurity Pharmaceuticals, Inc. $19.1411/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1242672014 CMS
GENZYME CORPORATION $20.8610/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233624184 CMS
Gilead Sciences, Inc. $19.2205/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234536450 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $416.26 6
PY2020 $99.00 1
PY2021 $24.68 2
PY2022 $1,019.78 7
PY2023 $2,636.63 8
PY2024 $382.04 5
PY2025 $88.44 5

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $741,878.53 46
PY2024 Principal investigator $292,913.76 72
PY2023 Principal investigator $1,493,338.71 38
PY2022 Principal investigator $500,825.07 28
PY2021 Principal investigator $491,385.16 69
PY2020 Recipient $139.26 1
PY2020 Principal investigator $518,626.07 135
PY2019 Principal investigator $72,202.28 102

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

46 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme LLC $22,150.54 12/31/2025 Non-covered Recipient Entity
CARTI Cancer Center
A Randomized Phase 3 Study Evaluating Cystectomy with Perioperative Pembrolizumab and Cystectomy with Perioperative Enfortumab Vedotin and Pembrolizumab versus Cystectomy Alone in Participants who are Cisplatin-Ineligible or Decline Cisplatin with Muscle- No dispute reported 06/30/2026 1232927923
Principal investigator 1 BeOne Medicines Ltd. $350.00 12/17/2025 Non-covered Recipient Entity
Central Arkansas Radiation Therapy Institute, Inc
An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients with B-cell Malignancies No dispute reported 06/30/2026 1190329301
Principal investigator 1 Caris MPI, Inc. $13,975.00 12/11/2025 Non-covered Recipient Entity
CENTRAL ARKANSAS RADIATION THERAPY INSTITUTE INC DBA CARTI
THE CARIS BIOREPOSITORY RESEARCH PROTOCOL No dispute reported 06/30/2026 1234289964
Principal investigator 1 PFIZER INC. $1,706.40 12/03/2025 Non-covered Recipient Entity
CARTI Cancer Center
A PHASE 2B3 RANDOMIZED DOUBLEBLIND STUDY TO INVESTIGATE THE EFFICACY SAFETY AND TOLERABILITY OF PONSEGROMAB PF06946860 COMPARED WITH PLACEBO BOTH WITH BACKGROUND FIRSTLINE CHEMOTHERAPY IN ADULT PARTICIPANTS WITH CACHEXIA AND METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA No dispute reported 06/30/2026 1228732177
Principal investigator 1 PFIZER INC. $2,257.20 12/03/2025 Non-covered Recipient Entity
CARTI Cancer Center
A PHASE 2B3 RANDOMIZED DOUBLEBLIND STUDY TO INVESTIGATE THE EFFICACY SAFETY AND TOLERABILITY OF PONSEGROMAB PF06946860 COMPARED WITH PLACEBO BOTH WITH BACKGROUND FIRSTLINE CHEMOTHERAPY IN ADULT PARTICIPANTS WITH CACHEXIA AND METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA No dispute reported 06/30/2026 1228735552
Principal investigator 1 BeOne Medicines Ltd. $1,258.00 12/01/2025 Non-covered Recipient Entity
Central Arkansas Radiation Therapy Institute, Inc
An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients with B-cell Malignancies No dispute reported 06/30/2026 1190334488
Principal investigator 1 BeOne Medicines Ltd. $1,258.00 12/01/2025 Non-covered Recipient Entity
Central Arkansas Radiation Therapy Institute, Inc
An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients with B-cell Malignancies No dispute reported 06/30/2026 1190341570
Principal investigator 1 PFIZER INC. $329.00 11/13/2025 Non-covered Recipient Entity
CARTI CANCER CTR
A PHASE 2B3 RANDOMIZED DOUBLEBLIND STUDY TO INVESTIGATE THE EFFICACY SAFETY AND TOLERABILITY OF PONSEGROMAB PF06946860 COMPARED WITH PLACEBO BOTH WITH BACKGROUND FIRSTLINE CHEMOTHERAPY IN ADULT PARTICIPANTS WITH CACHEXIA AND METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA No dispute reported 06/30/2026 1228728241
Principal investigator 1 BeOne Medicines Ltd. $1,258.00 09/10/2025 Non-covered Recipient Entity
Central Arkansas Radiation Therapy Institute, Inc
An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies No dispute reported 06/30/2026 1190327057
Principal investigator 1 BeOne Medicines Ltd. $1,258.00 09/10/2025 Non-covered Recipient Entity
Central Arkansas Radiation Therapy Institute, Inc
An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies No dispute reported 06/30/2026 1190327113
Principal investigator 1 Merck Sharp & Dohme LLC $33,210.40 08/31/2025 Non-covered Recipient Entity
CARTI Cancer Center
A Phase 3 Study of Pembrolizumab in combination with Carboplatin,Taxane Paclitaxel or Nab-paclitaxel followed by Pembrolizumab with or without maintenance MK 2870 in the First-line Treatment of Metastatic Squamous Non-small Cell Lung Cancer No dispute reported 06/30/2026 1232924364
Principal investigator 1 BeOne Medicines Ltd. $104,800.00 08/05/2025 Non-covered Recipient Entity
Central Arkansas Radiation Therapy Institute, Inc
An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies No dispute reported 06/30/2026 1190330209
Principal investigator 1 BeOne Medicines Ltd. $209,600.00 07/23/2025 Non-covered Recipient Entity
Central Arkansas Radiation Therapy Institute, Inc
An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies No dispute reported 06/30/2026 1190330223
Principal investigator 1 Caris MPI, Inc. $15,300.00 07/23/2025 Non-covered Recipient Entity
CENTRAL ARKANSAS RADIATION THERAPY INSTITUTE INC DBA CARTI
THE CARIS BIOREPOSITORY RESEARCH PROTOCOL No dispute reported 06/30/2026 1234289307
Principal investigator 1 BeOne Medicines Ltd. $151.00 07/09/2025 Non-covered Recipient Entity
Central Arkansas Radiation Therapy Institute, Inc
An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies No dispute reported 06/30/2026 1190327043
Principal investigator 1 BeOne Medicines Ltd. $1,940.00 07/09/2025 Non-covered Recipient Entity
Central Arkansas Radiation Therapy Institute, Inc
An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies No dispute reported 06/30/2026 1190327103
Principal investigator 1 BeOne Medicines Ltd. $500.00 07/09/2025 Non-covered Recipient Entity
Central Arkansas Radiation Therapy Institute, Inc
An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies No dispute reported 06/30/2026 1190327231
Principal investigator 1 BeOne Medicines Ltd. $45.00 07/09/2025 Non-covered Recipient Entity
Central Arkansas Radiation Therapy Institute, Inc
An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies No dispute reported 06/30/2026 1190327263
Principal investigator 1 BeOne Medicines Ltd. $2,375.00 07/09/2025 Non-covered Recipient Entity
Central Arkansas Radiation Therapy Institute, Inc
An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies No dispute reported 06/30/2026 1190327293
Principal investigator 1 BeOne Medicines Ltd. $2,188.00 07/09/2025 Non-covered Recipient Entity
Central Arkansas Radiation Therapy Institute, Inc
An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies No dispute reported 06/30/2026 1190327311
Principal investigator 1 BeOne Medicines Ltd. $150.00 06/23/2025 Non-covered Recipient Entity
Central Arkansas Radiation Therapy Institute, Inc
An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies No dispute reported 06/30/2026 1190331279
Principal investigator 1 BeOne Medicines Ltd. $1,258.00 06/20/2025 Non-covered Recipient Entity
Central Arkansas Radiation Therapy Institute, Inc
An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies No dispute reported 06/30/2026 1190343040
Principal investigator 1 BeOne Medicines Ltd. $52,400.00 06/16/2025 Non-covered Recipient Entity
Central Arkansas Radiation Therapy Institute, Inc
An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies No dispute reported 06/30/2026 1190330257
Principal investigator 1 PFIZER INC. $12,535.02 05/30/2025 Non-covered Recipient Entity
Central Arkansas Radiation Therapy Institute Inc dba CARTI
A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY SAFETY AND TOLERABILITY OF PONSEGROMAB IN PATIENTS WITH CANCER CACHEXIA AND ELEVATED CONCENTRATIONS OF GDF15 FOLLOWED BY AN OPTIONAL OPENLABEL TREATMENT PERIOD No dispute reported 06/30/2026 1228765172
Principal investigator 1 BeOne Medicines Ltd. $52,400.00 05/29/2025 Non-covered Recipient Entity
Central Arkansas Radiation Therapy Institute, Inc
An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies No dispute reported 06/30/2026 1190330277
Principal investigator 1 BeiGene, Ltd. $1,940.00 05/23/2025 Non-covered Recipient Entity
Central Arkansas Radiation Therapy Institute, Inc
An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies No dispute reported 06/30/2026 1190320690
Principal investigator 1 BeiGene, Ltd. $2,188.00 05/23/2025 Non-covered Recipient Entity
Central Arkansas Radiation Therapy Institute, Inc
An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies No dispute reported 06/30/2026 1190320698
Principal investigator 1 BeiGene, Ltd. $196.00 05/23/2025 Non-covered Recipient Entity
Central Arkansas Radiation Therapy Institute, Inc
An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies No dispute reported 06/30/2026 1190320710
Principal investigator 1 BeiGene, Ltd. $2,375.00 05/23/2025 Non-covered Recipient Entity
Central Arkansas Radiation Therapy Institute, Inc
An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies No dispute reported 06/30/2026 1190322954
Principal investigator 1 BeiGene, Ltd. $1,258.00 05/16/2025 Non-covered Recipient Entity
Central Arkansas Radiation Therapy Institute, Inc
An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies No dispute reported 06/30/2026 1190320728
Principal investigator 1 BeiGene, Ltd. $52,400.00 03/24/2025 Non-covered Recipient Entity
Central Arkansas Radiation Therapy Institute, Inc
An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies No dispute reported 06/30/2026 1190322108
Principal investigator 1 BeiGene, Ltd. $1,258.00 03/14/2025 Non-covered Recipient Entity
Central Arkansas Radiation Therapy Institute, Inc
An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies No dispute reported 06/30/2026 1190319976
Principal investigator 1 BeiGene, Ltd. $1,258.00 03/14/2025 Non-covered Recipient Entity
Central Arkansas Radiation Therapy Institute, Inc
An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies No dispute reported 06/30/2026 1190324664
Principal investigator 1 BeiGene, Ltd. $52,400.00 03/06/2025 Non-covered Recipient Entity
Central Arkansas Radiation Therapy Institute, Inc
An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies No dispute reported 06/30/2026 1190323688
Principal investigator 1 BeiGene, Ltd. $350.00 02/28/2025 Non-covered Recipient Entity
Central Arkansas Radiation Therapy Institute, Inc
An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies No dispute reported 06/30/2026 1190319978
Principal investigator 1 BeiGene, Ltd. $500.00 02/28/2025 Non-covered Recipient Entity
Central Arkansas Radiation Therapy Institute, Inc
An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies No dispute reported 06/30/2026 1190320084
Principal investigator 1 PFIZER INC. $1,126.25 02/14/2025 Non-covered Recipient Entity
Central Arkansas Radiation Therapy Institute Inc dba CARTI
A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY SAFETY AND TOLERABILITY OF PONSEGROMAB IN PATIENTS WITH CANCER CACHEXIA AND ELEVATED CONCENTRATIONS OF GDF15 FOLLOWED BY AN OPTIONAL OPENLABEL TREATMENT PERIOD No dispute reported 06/30/2026 1228757450
Principal investigator 1 BeiGene, Ltd. $392.00 01/06/2025 Non-covered Recipient Entity
Central Arkansas Radiation Therapy Institute, Inc
An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies No dispute reported 06/30/2026 1190319944
Principal investigator 1 BeiGene, Ltd. $4,750.00 01/06/2025 Non-covered Recipient Entity
Central Arkansas Radiation Therapy Institute, Inc
An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies No dispute reported 06/30/2026 1190319962
Principal investigator 1 BeiGene, Ltd. $3,880.00 01/06/2025 Non-covered Recipient Entity
Central Arkansas Radiation Therapy Institute, Inc
An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies No dispute reported 06/30/2026 1190319972
Principal investigator 1 BeiGene, Ltd. $500.00 01/06/2025 Non-covered Recipient Entity
Central Arkansas Radiation Therapy Institute, Inc
An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies No dispute reported 06/30/2026 1190320072
Principal investigator 1 BeiGene, Ltd. $500.00 01/06/2025 Non-covered Recipient Entity
Central Arkansas Radiation Therapy Institute, Inc
An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies No dispute reported 06/30/2026 1190324300
Principal investigator 1 BeiGene, Ltd. $4,376.00 01/06/2025 Non-covered Recipient Entity
Central Arkansas Radiation Therapy Institute, Inc
An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies No dispute reported 06/30/2026 1190324640
Principal investigator 1 BeiGene, Ltd. $1,000.00 01/06/2025 Non-covered Recipient Entity
Central Arkansas Radiation Therapy Institute, Inc
An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies No dispute reported 06/30/2026 1190324698
Principal investigator 1 AstraZeneca Pharmaceuticals LP $24,178.72 01/03/2025 Non-covered Recipient Entity
CARTI PHARMACY
A Phase III, Randomised, Open-label, Multicentre, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination with Durvalumab and Carboplatin Versus Pembrolizumab in Combination with Platinum-based Chemotherapy for the First-line Treatment of Patients with Locally Advanced or Metastatic NSCLC without Actionable Genomic Alterations (D926NC00001; AVANZAR) No dispute reported 06/30/2026 1185549197
Principal investigator 1 BeiGene, Ltd. $50,400.00 01/02/2025 Non-covered Recipient Entity
Central Arkansas Radiation Therapy Institute, Inc
An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies No dispute reported 06/30/2026 1190323722